NME1 (NME1) was identified because of its reduced mRNA transcript levels in highly metastatic cells. Nucleoside diphosphate kinase (NDK) exists as a hexamer composed of 'A' (encoded by NME1) and 'B' (encoded by NME2) isoforms. Mutations in NME1 have been identified in aggressive neuroblastomas. Two transcript variants encoding different isoforms have been found for NME1. Co-transcription of NME1 and the neighboring downstream gene (NME2) generates naturally-occurring transcripts (NME1-NME2), which encodes a fusion protein comprised of sequence sharing identity with each individual gene product.

NM23-H1 Polyclonal Antibody detects endogenous levels of NM23-H1 protein.

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB: 1:500-1:2000, IHC-p: 1:100-1:300, ELISA: 1:20000. Not yet tested in other applications.

NM23-H1 Polyclonal Antibody product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Find more details at http://www.abbkine.com/product/nm23-h1-polyclonal-antibody-abp51970.